Loading organizations...
Key people at Consulta Remédios.
Consulta Remédios is a São Paulo, Brazil-based online healthcare marketplace that enables consumers to search for medications, compare pharmacy prices, and access detailed pharmaceutical information. The platform currently attracts over 30 million unique monthly users who utilize the system to find treatments, personal care products, and digital prescription services. Operating with an estimated annual revenue between R$2 million and R$4.8 million alongside a registered capital social of R$41.8 million, the company generates income through sales leads and strategic pharmacy partnerships. To expand its digital health ecosystem, the organization acquired the digital prescription platform Receita Digital and previously secured strategic investment from the Brazilian holding company Grupo Codal. Consulta Remédios was originally conceptualized by Valdir Groto and officially founded as a legal entity in 2006, with Paulo Vion serving as founder and chief executive officer.
Key people at Consulta Remédios.
Consulta Remédios is Brazil's leading online pharmaceutical marketplace, founded in 2000, that enables users to compare prices, access information on medications, and purchase a wide range of health products including prescription and over-the-counter drugs, personal care items, cosmetics, beauty products, and veterinary supplies directly from pharmacies with home delivery.[1][2][3][4] It serves millions of Brazilian consumers and healthcare professionals by aggregating small, medium, and large pharmacy retailers, solving the problem of opaque pricing and limited access to affordable healthcare goods through transparent comparisons, drug interaction details, and nearby pharmacy locations.[1][4][5] With around 50-85 employees, $6.8 million in annual revenue, and 13 million web visits, the platform holds a dominant position, capturing 8 out of 10 online searches for medicine prices in Brazil.[2][3][5]
Founded in 2000 in Curitiba, Paraná, Brazil, Consulta Remédios emerged amid shifting consumer habits toward online information and purchasing, aiming to provide reliable data and savings on medicines and pharmaceutical products.[1][2][3] The company has a co-founder serving as CEO and CTO Sérgio Furlaneto leading technology efforts, building on two decades of market presence to become integral to daily healthcare decisions.[2][3] Early traction stemmed from its role as a price comparison tool, evolving into a full digital marketplace that bridges consumers with pharmacies, achieving high web rankings and massive user reach without specified pivotal funding events in available data.[3][4][5]
Consulta Remédios rides the wave of digital health transformation in Latin America, particularly Brazil's booming e-pharmacy sector fueled by rising internet penetration, post-pandemic online shopping shifts, and demand for affordable healthcare amid economic pressures.[4][5] Its timing aligns with e-commerce growth in retail pharmacy, where consumers seek transparency over traditional chains like Raia Drogasil or Pague Menos, positioning it as a disruptor by democratizing access without physical stores.[1] Market forces like increasing mobile usage and regulatory pushes for generic drugs favor its model, while it influences the ecosystem by aggregating fragmented pharmacies, boosting small retailers' visibility, and pioneering retail media in pharma for targeted health ads.[4]
Consulta Remédios is poised for accelerated growth through its 2025 retail media expansion, leveraging first-party data for personalized ads and deeper pharmacy integrations amid Brazil's digital health surge.[4] Trends like AI-driven personalization, further e-pharma consolidation, and rising wellness spending will shape its path, potentially scaling revenue beyond $6.8M via international outreach or advanced features like telehealth ties. Its influence may evolve from price comparator to full-service health platform, solidifying dominance in accessible care and reinforcing its foundational mission of savings and trust for millions.[3][4][5]
